Abiraterone slows advanced prostate cancer, helps patients live longer
A clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the relative risk of death by 37%. The 3-year survival ...
Jun 5, 2017
0
1